Faron Pharmaceuticals - Innovativa medicinska lösningar (Del 2)


Omprogrammering av korskommunikation mellan T-celler och myeloidceller övervinner immunresistens vid kolorektalcancer


En mycket imponerande artikel från Mount Sinai / Cell Reports Medicine -CRC paperi konstaterar återigen:

According to the study the combination therapy achieved up to 100 percent tumor clearance in models of mismatch repair-deficient colorectal cancer, and more than 70 percent clearance in mismatch repair-proficient tumors, which are typically resistant to immunotherapy.

“This approach effectively reprograms the tumor microenvironment,” said first author Guillaume Mestrallet, PhD, a postdoctoral fellow in the Bhardwaj Lab at Mount Sinai. “By simultaneously reinvigorating T cells and targeting suppressive macrophages, we were able to restore immune coordination and generate powerful anti-tumor responses.”
Importantly, the study also demonstrated the development of immune memory, suggesting the potential for long-lasting protection against cancer recurrence. The findings have significant implications for the future of cancer treatment, supporting the development of rational combination immunotherapies that go beyond single-agent approaches

Mycket nära den biologiska logik som även Bex baseras på.

19 gillningar